Latest News - Product Launches and Updates

Tuesday, May 16, 2017 | Product Launches and Updates, Research and Publications, Stroke & Cerebrovascular

Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Thursday, May 04, 2017 | Neuromuscular & Immune Disorders, Product Launches and Updates, Research and Publications

MS Topography App Launches

A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation th…

Read the full story

Wednesday, May 03, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Product Launches and Updates, Research and Publications

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS Syste…

Read the full story

Wednesday, April 12, 2017 | FDA Approval/Clearance, Movement Disorders, Product Launches and Updates

First Treatment for Tardive Dyskinesia Approved in US

The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of…

Read the full story

Wednesday, January 25, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Product Launches and Updates

Memory Impairment Screening Tool Gains FDA Clearance

The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults at the point of care. CA…

Read the full story

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders, Personnel/Company News, Product Launches and Updates

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies…

Read the full story

Tuesday, November 01, 2016 | FDA Approval/Clearance, Product Launches and Updates

Portable Brain Monitoring Information System Gains FDA Clearance

A new portable ultrasound device designed for rapid triaging and monitoring of patients with brain disorders has been cleared by the FDA. The Lucid System uses Trans Cranial Doppler to non-invasively …

Read the full story

Thursday, March 24, 2016 | Product Launches and Updates

Novel Concussion Assessment Technology Wins Research Support from Mayo Clinic

Neuro Assessment Systems, Inc. and the Mayo clinic are set to collaborate on studying a new system for the assessment of central nervous system (CNS) changes associated with concussion, TBI, aging-rel…

Read the full story

Wednesday, March 23, 2016 | Product Launches and Updates

Epilepsy Drug Using 3D Printing Technology Now Available

Spritam (levetiracetam, Aprecia Pharmaceuticals), the FDA-approved oral drug using novel 3D printing technology, is now available as an adjunctive therapy in the treatment of partial onset seizures, m…

Read the full story

Tuesday, February 09, 2016 | Product Launches and Updates

Xeomin Now Available in 200-unit Single-Dose Vial

Merz Neuroscience has unveiled a new 200-unit single-dose vial of Xeomin (incobotulinumtoxinA). The new vial supports the dosing associated with the recently approved adult upper limb spasticity indic…

Read the full story

Tuesday, January 19, 2016 | Product Launches and Updates

EMD Serono Takes Over Sole US Rights to Rebif

EMD Serono has taken over the sole US rights to Rebif (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS) to decrease the frequency of relapses and delay the occurrenc…

Read the full story

Wednesday, December 02, 2015 | Product Launches and Updates

FDA Grants StimRelieve IDE Approval to Investigate Wireless Device for CranioFacial Nerve Pain

StimRelieve has received FDA Investigational Device Exemption (IDE) approval to launch a clinical trial of its percutaneously implantable device for the treatment of refractory craniofacial neuropathi…

Read the full story

Monday, August 24, 2015 | Product Launches and Updates

Researchers Funded by the National MS Society Build on Commercial Partnership to Develop Diagnostic Test for MS

A team of researchers from around the country have published findings indicating the accuracy of MSPrecise® (Amarantus Bioscience Holdings, Inc.), a laboratory test under development for diagnosing M…

Read the full story

Friday, July 31, 2015 | Product Launches and Updates

Codman Neuro Launches Family of Coils for Treatment of Brain Aneurysms

Codman Neuro, part of DePuy Synthes Companies of Johnson and Johnson, has introduced a new platform of embolic coils for the treatment of brain aneurysms, supported by an enhanced detachment system de…

Read the full story
Load More